AR015122A1 - USEFUL COMPOUNDS FOR INHIBITION OF PROTEIN TRANSFER TO FARNESILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. - Google Patents

USEFUL COMPOUNDS FOR INHIBITION OF PROTEIN TRANSFER TO FARNESILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.

Info

Publication number
AR015122A1
AR015122A1 ARP980102863A ARP980102863A AR015122A1 AR 015122 A1 AR015122 A1 AR 015122A1 AR P980102863 A ARP980102863 A AR P980102863A AR P980102863 A ARP980102863 A AR P980102863A AR 015122 A1 AR015122 A1 AR 015122A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
alkenyl
halo
co2r10
Prior art date
Application number
ARP980102863A
Other languages
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR015122A1 publication Critical patent/AR015122A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Un compuesto util para la inhibicion de transferasa de proteína al farnesilo que tiene la formula I o una sal farmacéuticamente aceptable o un solvato delos mismos, en los que: A es alquilo, halo o H; B es metilo, halo o H, la línea de trazosreprese nta un doble enlace opcional; R5, R6, R7 y R8 estánindependientemente seleccionados del grupo que consiste en H, -CF3, -COR10, alquilo o arilo, estando dicho alquilo o arilo opcionalmente substituido con -OR10,-SR10, -S(O)tR11, -NR10COOR11,-N(R10)2, -NO2, -COR10, -OCOR10, -OCO2R11, -CO2R10, OPO3R10 o uno de R5, R6, R7 y R8 pueden tomarse en combinacion con R40 talcomo se define a continuacion para representar -(CH2)r- donde r es 1 a 4 que puede estar substituido con alquilo inferior,alcoxi inf erior, -CF3 o arilo, o R5se combina con R6 para representar =O o =S y/o R7 se combina con R8 para representar =O o =S; R10 representa H, alquilo, arilo o aralquilo, R11 representaalquilo o arilo; R40 representa H, arilo, alquilo,cicloalquilo, alquen ilo, alquinilo o -D donde -D representa II, donde R3 y R4 están independientementeseleccionados del grupo que consiste en H, halo, -CF3, -OR10, -COR10, -SR10, -S(O)tR11 (donde t es 0, 1 o 2),-SCN, -N(R10)2,-NR10R11, -NO2,-OC(O)R10, -CO2R10,-OCO2R11, -CN, -NHC(O)R10, -NHSO2R10, -CONHR10, -CONHCH2CH2OH, -NR10COOR11, III, -SR11C(O)OR11, -SR11N(R75)2 donde cada R75 está independientementeseleccionado de H y -C(O)OR11, benzotriazol-1-iloxi, tetrazol-5-iltio, otetrazol-5-iltio substituido, alquenilo ,alquenilo o alquilo, estando dicho grupoalquilo o alquenilo opcionalmente substituido con halo, -OR10 o -CO2R10; y W es O, S o NR10 donde R 10 es tal como se ha definido más arriba;dichos gruposcicloalquilo,alquenilo y alquinilo R40 están opcionalm ente substituidos con desde 1-3 grupos seleccionados de halo, -CON(R10)2, arilo, -CO2R10, -OR12, -SR12,-N(R10)2, -N(R10)CO2R11, -COR12, -NO2 o D donde -D, R10 y R11 son tal como se han definido más arriba yR 12 representa R10, -(CH2)mOR10 o -(CH2)qC OR10 dondeR10 es como se ha definido previamente, m es 1 a 4 y q es 0 a 4; dichos grupos alquenilo y alquinilo R 40 que no contienen -OH, -SH o -N(R10)2 en un carbonoA compound useful for the inhibition of farnesyl protein transferase having formula I or a pharmaceutically acceptable salt or solvate thereof, in which: A is alkyl, halo or H; B is methyl, halo or H, the dashed line represents an optional double bond; R5, R6, R7 and R8 are independently selected from the group consisting of H, -CF3, -COR10, alkyl or aryl, said alkyl or aryl being optionally substituted with -OR10, -SR10, -S (O) tR11, -NR10COOR11, -N (R10) 2, -NO2, -COR10, -OCOR10, -OCO2R11, -CO2R10, OPO3R10 or one of R5, R6, R7 and R8 can be taken in combination with R40 as defined below to represent - (CH2) r- where r is 1 to 4 which may be substituted with lower alkyl, lower alkoxy, -CF3 or aryl, or R5 is combined with R6 to represent = O o = S and / or R7 is combined with R8 to represent = O or = S; R10 represents H, alkyl, aryl or aralkyl, R11 represents alkyl or aryl; R40 represents H, aryl, alkyl, cycloalkyl, alkenyl, alkynyl or -D where -D represents II, where R3 and R4 are independently selected from the group consisting of H, halo, -CF3, -OR10, -COR10, -SR10, -S (O) tR11 (where t is 0, 1 or 2), - SCN, -N (R10) 2, -NR10R11, -NO2, -OC (O) R10, -CO2R10, -OCO2R11, -CN, - NHC (O) R10, -NHSO2R10, -CONHR10, -CONHCH2CH2OH, -NR10COOR11, III, -SR11C (O) OR11, -SR11N (R75) 2 where each R75 is independently selected from H and -C (O) OR11, benzotriazole- 1-yloxy, tetrazol-5-ylthio, substituted otetrazol-5-ylthio, alkenyl, alkenyl or alkyl, said group being alkyl or alkenyl optionally substituted by halo, -OR10 or -CO2R10; and W is O, S or NR10 where R 10 is as defined above; said cycloalkyl, alkenyl and alkynyl groups R40 are optionally substituted with from 1-3 groups selected from halo, -CON (R10) 2, aryl, -CO2R10, -OR12, -SR12, -N (R10) 2, -N (R10) CO2R11, -COR12, -NO2 or D where -D, R10 and R11 are as defined above and R 12 represents R10, - (CH2) mOR10 or - (CH2) qC OR10 where R10 is as previously defined, m is 1 to 4 and q is 0 to 4; said alkenyl and alkynyl groups R 40 which do not contain -OH, -SH or -N (R10) 2 in a carbon

ARP980102863A 1997-06-17 1998-06-16 USEFUL COMPOUNDS FOR INHIBITION OF PROTEIN TRANSFER TO FARNESILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. AR015122A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87774397A 1997-06-17 1997-06-17

Publications (1)

Publication Number Publication Date
AR015122A1 true AR015122A1 (en) 2001-04-18

Family

ID=25370623

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102863A AR015122A1 (en) 1997-06-17 1998-06-16 USEFUL COMPOUNDS FOR INHIBITION OF PROTEIN TRANSFER TO FARNESILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.

Country Status (13)

Country Link
EP (1) EP0989984A1 (en)
JP (1) JP2002504145A (en)
KR (1) KR20010013825A (en)
CN (1) CN1266432A (en)
AR (1) AR015122A1 (en)
AU (1) AU744153B2 (en)
CA (1) CA2293713C (en)
CO (1) CO4940447A1 (en)
HU (1) HUP0004274A3 (en)
IL (1) IL133388A0 (en)
NZ (1) NZ501418A (en)
WO (1) WO1998057961A1 (en)
ZA (1) ZA985214B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764387A1 (en) 2009-06-05 2010-12-09 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE210652T1 (en) * 1993-10-15 2001-12-15 Schering Corp TRICYCLIC CARBAMAT DERIVATIVES FOR INHIBITING G-PROTEIN FUNCTION AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Pharmaceutical compositions for inhibition of g-protein function and for treatment of proliferative diseases containing tricyclic compounds some such compounds and process for preparing part of them
CN1326847C (en) * 1995-12-22 2007-07-18 先灵公司 Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases

Also Published As

Publication number Publication date
ZA985214B (en) 1999-01-07
HUP0004274A2 (en) 2001-08-28
HUP0004274A3 (en) 2002-03-28
JP2002504145A (en) 2002-02-05
CN1266432A (en) 2000-09-13
CO4940447A1 (en) 2000-07-24
AU8058198A (en) 1999-01-04
EP0989984A1 (en) 2000-04-05
CA2293713A1 (en) 1998-12-23
CA2293713C (en) 2006-12-05
IL133388A0 (en) 2001-04-30
KR20010013825A (en) 2001-02-26
WO1998057961A1 (en) 1998-12-23
NZ501418A (en) 2001-04-27
AU744153B2 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
HUP0000121A2 (en) Tricyclic inhibitors of farnesyl protein transferase, pharmaceutical compositions containing them and their use
AR002722A1 (en) TRICYCLIC AMIDE AND UREA COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO INHIBIT THE ABNORMAL DEVELOPMENT OF CELLS
FI875202A (en) STEROIDER MED EN SPIRANRING I 17-STAELLNING, FOERFARANDE FOER FRAMSTAELLNING AV DESSA OCH ANVAENDNING AV DESSA.
UY24854A1 (en) METALLOPROTEASE SULFAMIDES INHIBITORS
DE69627377D1 (en) INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASE
AR051092A1 (en) HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA
DE50301525D1 (en) Dental materials based on acrylic ester phosphonic acids
DE69923692D1 (en) GROWTH HORMONE RELEASING OXINDOL DERIVATIVES
ES2237963T3 (en) INHIBITORS OF FARNESIL PROTEINA TRANSFERASA.
AR026352A1 (en) IMIDAZOPIRIDINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE VII.
DE59103664D1 (en) Process for the inhibition and destruction of peroxides in dialkyl ethers.
FI860369A0 (en) IMMEDIATE SOLUTIONS, DERAS FRAMSTAELLNING OCH ANVAENDNING SAMT DESSA DERIVAT INNEHAOLLANDE PHARMACEUTICAL COMPOSITION.
FR2719043B1 (en) New bicyclic-aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses.
ES2196308T3 (en) DERIVED FROM 2-CIANOIMINOIMIDAZOL THAT INHIBIT THE PDE IV.
ZA978652B (en) Flavone compounds, process for preparing them and pharmaceutical compositions containing them.
NZ217398A (en) Angiotensin-converting enzyme(ace)inhibitor and pharmaceutical composition
DK1026167T3 (en) Tricyclic triazolobenzazepine derivatives, process for their preparation and antiallergic agents
TR199802255T2 (en) Substances that repel arthropods.
AR015122A1 (en) USEFUL COMPOUNDS FOR INHIBITION OF PROTEIN TRANSFER TO FARNESILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
ES466626A1 (en) Fluorescent azolyl benzocoumarin dyestuffs
ES8301216A1 (en) Substituted enantholactam derivatives as antihypertensives, a process for preparing and a pharmaceutical composition containing them, and intermediates.
ES2106439T3 (en) 5- (PIPERAZINILALQUIL) -1,5-BENZOTIAZEPINONAS USEFUL AS ANTIGONISTS OF CALCIUM.
AR012847A1 (en) ERYTHROMYCIN-DERIVED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, TREATMENT PROCEDURES WITH SUCH COMPOUNDS, PROCEDURE FOR PREPARING SUCH COMPOUNDS
TW333525B (en) New perhydroisoindole derivatives, their preparation and the pharmaceutical compositions which contain them the invention relates to perhydroisoindole derivatives of general formula (I), and their salts when they exist advantageously as neurokinin A antagonists.
ES2059551T3 (en) NEW IMIDAZO-BENZODIAZEPINES AND THEIR ADDITIONAL SALTS WITH ACIDS, THEIR PROCEDURE AND THE INTERMEDIATE PREPARATION PRODUCTS, THEIR APPLICATION AS MEDICINES AND COMPOSITIONS THAT CONTAIN THEM.

Legal Events

Date Code Title Description
FB Suspension of granting procedure